Minicircle, an Austin-based plasmid gene therapy company, is one of ten finalists in the $101 million XPRIZE Healthspan competition, which requires demonstrating restored muscle, cognitive and immune function in adults aged 50 to 80. The company's non-viral circular DNA platform is designed to be redosable and to carry instructions for multiple genes simultaneously, addressing several aging pathways in parallel. Finalists receive $1 million toward placebo-controlled human trials, with Grand Prize results due in 2030.
Key Points
- Ten finalists remain from 1,400 teams across 58 countries
- Non-viral DNA loops allow repeat dosing and multi-gene targeting
- Trial endpoints: muscle, cognitive and immune function restoration
Longevity Analysis
The competition's endpoints mark a shift away from surrogate biomarkers toward measurable restoration of function — strength, cognition and immune responsiveness assessed together rather than in isolation. That framing acknowledges what single-pathway interventions consistently miss: aging proceeds as parallel decline across muscle, mitochondrial efficiency, immune surveillance and inflammatory tone, and an intervention that moves one marker rarely moves the person. Whether redosable non-viral delivery can act on several of those fronts at once remains an open question, but the trial design itself sets a standard of evidence the field has largely lacked.
Original published by Longevity.Technology, by Kyle Umipig.